Table 1.
Synthesis of psoriasis risk factors reporting reference number, first author surname, year of publication, population risk factors reported in each study and the type of psoriasis
Ref. | Year | Studied population | Psoriasis risk factors | Type of psoriasis |
Barrea et al[29] | 2016 | Human | Obesity | Not specified |
Kanemaru et al[68] | 2015 | Animal - Mice | Obesity | Psoriasiform dermatitis |
Dauden et al[30] | 2018 | Human | Metabolic disorders | Not specified |
Barrea et al[31] | 2017 | Human | Reduction vitamin D | Not specified |
Lin et al[56] | 2016 | Human | Oxidative stress | Not specified |
Yang et al[67] | 2018 | Animal - Mice | 12-O-tetradecanoylphorbol-13-acetate administration | Psoriasis-like skin lesions |
Ottman et al[70] | 2012 | Human | Beta-hemolytic streptococcal infections | Guttate psoriasis |
Zeng et al[71] | 2017 | Human | Staphylococcus aureus, Malassezia and Candida albicans infections | Not specified |
Alekseyenko et al[72] | 2013 | Human | Corynebacterium, Propionibacterium, Staphylococcus, and Streptococcus infections | Psoriatic plaques |
Baker et al[73] | 2006 | Human | Higher numbers of peptidoglycan-containing cells | Guttate and chronic plaques |
Oliveira Mde et al[75] | 2015 | Human | Inflammatory bowel disease (i.e., Crohn’s disease) | Not specified |
Scher et al[76] | 2015 | Human | Significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio in gut microbiota | Psoriasic arthritis |
Tan et al[85] | 2018 | Human | Reduction of Coprococcus species and Akkermansia muciniphila in gut microbiota | Psoriatic arthritis |